Oragenics Inc.
OGEN Real Time Price USDRecent trades of OGEN by members of U.S. Congress
No Congress Trading data for this ticker
Congress Trading Dashboard
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
---|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Recently reported changes by institutional investors
Quarterly net insider trading by OGEN's directors and management
Government lobbying spending instances
-
$10,000 Jul 19, 2021 Issue: Defense
-
$10,000 Apr 20, 2021 Issue: Defense
-
$50,000 Nov 02, 2020 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$50,000 Oct 20, 2020 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$40,000 Jul 20, 2020 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
-
$10,000 Jan 19, 2011 Issue: None
-
$10,000 Oct 18, 2010 Issue: Health Issues
-
$10,000 Jul 19, 2010 Issue: Health Issues
-
$10,000 Apr 16, 2010 Issue: Budget/Appropriations
Estimated quarterly lobbying spending
New patents grants
No new patents for this ticker
U.S. Patents DashboardFederal grants, loans, and purchases
No Government Contracts for this ticker
Government Contracts DashboardEstimated quarterly amount awarded from public contracts
Number of mentions of OGEN in WallStreetBets Daily Discussion
Recent insights relating to OGEN
Recent picks made for OGEN stock on CNBC
ETFs with the largest estimated holdings in OGEN
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view OGEN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.